Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of alopecia areata research as Nektar Therapeutics prepares to discuss 52-week REZOLVE-AA Phase 2b topline results for rezpegaldesleukin in severe-to-very-severe alopecia areata.
Pharma & Biotech

Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?

Nektar will discuss 52-week REZOLVE-AA data for rezpegaldesleukin on April 20. Find out what the alopecia areata catalyst could mean.

Read More
Representative image of antibody-drug conjugate cancer research, illustrating the next-generation ADC platform strategy highlighted by Whitehawk Therapeutics at AACR 2026.
Pharma & Biotech

Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?

Whitehawk Therapeutics unveiled AACR 2026 data for three ADCs. Read what it means for pipeline differentiation, risk, and investor sentiment.

Read More
Representative image of a catheter-based pulmonary artery denervation procedure, illustrating the kind of interventional therapy at the center of Pulnovo Medical’s $100 million financing round led by Medtronic.
Medical Devices & Diagnostics

Medtronic backs Pulnovo Medical in $100m round to expand PADN in pulmonary hypertension

Pulnovo Medical raised $100 million with Medtronic backing. Read what it means for PADN, pulmonary hypertension, heart failure, and device markets.

Read More
Representative image of a bispecific antibody-drug conjugate in a cancer research setting, illustrating the science behind CStone Pharmaceuticals’ AACR 2026 update on CS5007, CS5006, and CS5008 oncology pipeline candidates.
Pharma & Biotech

Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update

CStone Pharmaceuticals unveiled three ADC programs at AACR 2026. Read what CS5007, CS5006, and CS5008 could mean for oncology development.

Read More
Orthogon Therapeutics funding round puts fresh focus on BK virus risk in transplant patients
Pharma & Biotech

Orthogon Therapeutics adds $11m for BK virus drug, targeting one of transplant medicine’s toughest gaps

Orthogon Therapeutics raised $11M more for its BK virus drug program. Read why this transplant antiviral story could matter far beyond niche biotech.

Read More
Representative image of topical plaque psoriasis treatment and China market expansion, illustrating LEO Pharma’s Enstilar approval as the company targets growth in the world’s largest psoriasis patient market.
Pharma & Biotech

LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?

LEO Pharma has won China approval for Enstilar in plaque psoriasis. Read what it means for competition, access, and dermatology growth.

Read More
Representative image of osteoporosis research and denosumab biosimilar treatment, as Samsung Bioepis presents new SB16 subgroup efficacy data at WCO-IOF-ESCEO 2026.
Pharma & Biotech

Obodence at WCO 2026: Samsung Bioepis sharpens the clinical case for SB16 adoption

Samsung Bioepis presented new SB16 subgroup data at WCO 2026. Read what it means for Obodence adoption, biosimilar trust, and osteoporosis care.

Read More
Khondrion Phase 3 KHENERFIN study of sonlicromanol in m.3243A>G primary mitochondrial disease, a representative image of rare disease drug development and mitochondrial therapy research.
Pharma & Biotech

Khondrion moves sonlicromanol into Phase 3, but can KHENERFIN finally crack mitochondrial disease?

Khondrion has dosed the first patient in Phase 3 KHENERFIN for sonlicromanol. Read what it could change in mitochondrial disease treatment.

Read More
Bruker expands MALDI Biotyper workflows as microbiology labs push for faster outbreak detection
Medical Devices & Diagnostics

Why Bruker’s ESCMID 2026 microbiology expansion could matter for hospital labs and infection control

Bruker expanded its microbiology portfolio at ESCMID 2026. Read what the new MALDI and outbreak tools could mean for labs and infection control.

Read More
Pharma & Biotech

Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?

Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.

Read More